Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (29)

B-03

Overview and implementation of multi criteria decision analysis (MCDA) for benefit-risk assessment

Wednesday 09:00-09:30

B-04Andreas Kouroumalis

European regulatory views on benefit-risk assessment methodologies – role of MCDA and other model-based approaches

Wednesday 09:30-10:00

B-05Kevin Marsh

Current practices and gaps in benefit-risk assessment: opportunities for combining MCDA with model-based approaches

Wednesday 10:00-10:30

B-07Neeraj Gupta

Model-Informed Drug Development (MIDD) for ixazomib, an oral proteasome inhibitor

Wednesday 12:00-12:20

B-08Nadia Terranova

Simulation analysis of absolute lymphocytes counts (ALC) and relapse rate (RR) following cladribine (re-)treatment rules in subjects with relapsing-remitting multiple sclerosis (RRMS)

Wednesday 12:20-12:40

B-11Joe Standing

Scaling pharmacodynamics in children: Lessons from immunology, infectious diseases and critical care

Wednesday 14:10-14:50

B-12Nick Holford

Scaling renal function in neonates and infants to describe the pharmacodynamics of antibiotic nephrotoxicity

Wednesday 14:50-15:10

B-14Hanna Silber Baumann

Using pharmacokinetic simulation to guide dose escalation decisions for targeted IL2v immunocytokines

Wednesday 16:40-17:00

B-15Simon Buatois

Modelling approaches in dose finding clinical trial: Simulation-based study comparing predictive performances of model averaging and model selection.

Wednesday 17:00-17:20

B-16Yuri Kheifetz

Model-based individual managing of thrombocytopenia during multi-cyclic chemotherapy

Wednesday 17:20-17:40

B-17Jurgen Langenhorst

High exposure to fludarabine in conditioning prior to allogeneic hematopoietic cell transplantation predicts impaired CD4 reconstitution and lower probability of survival

Wednesday 17:40-18:00

C-01Elisa Borella

Paediatric trial design optimization using prior knowledge in combination with modelling & simulations

Thursday 08:30-08:55

C-02John Diep

Host-Pathogen interactions: A mechanism-based disease progression model to describe the pathogenesis of Acinetobacter baumannii pneumonia

Thursday 08:55-09:20

C-03Morris Muliaditan

Model-based rationale for drug combinations in tuberculosis

Thursday 09:20-09:45

C-06Robert Leary

An overview of non-parametric estimation methods used in population analysis

Thursday 11:20-12:00

C-07Mats Karlsson

A comparison of performance between parametric and nonparametric estimation for nonlinear mixed-effects models

Thursday 12:00-12:20

C-11Kristin Karlsson

Regulatory pharmacometrics in the EU in practice and the role of the Modelling and Simulation Working Group

Thursday 13:45-14:15

C-12Anna Nordmark

The new draft EMA Guidance on PBPK – The qualification of the intended use concept

Thursday 14:15-14:45

C-15Wojciech Krzyzanski

Correction of the likelihood function as an alternative for imputing missing covariates

Thursday 16:20-16:40

C-16Henrik Bjugård Nyberg

SADDLE_RESET: more robust parameter estimation with a check for local practical identifiability

Thursday 16:40-17:00

C-17Dmitry Onishchenko

Joint modeling of overall survival and tumor size dynamics in non-small cell lung cancer: Clinical trial simulations and validation of predictions at study and subject levels

Thursday 17:00-17:20

C-18Eva Germovsek

Handling frequent observations of composite scores: Application to PROs in COPD

Thursday 17:20-17:40

D-01Markus Krauß

Translational systems pharmacology for acquisition of knowledge and prediction of drug pharmacokinetics across patient populations

Friday 09:00-09:20

D-02Robin Michelet

PBPK modeling of propofol using the middle out approach

Friday 09:20-09:40

D-03Miro Eigenmann

Therapeutic antibody concentrations at the biophase

Friday 09:40-10:00

D-04Alan Maloney

The 6 biggest pharmacometrics modelling mistakes!

Friday 10:00-10:25

D-07Richard Höglund

Pharmacokinetic-pharmacodynamic modelling of artesunate in patients with drug resistant and sensitive malaria

Friday 11:15-11:35

D-08Salvatore D'Agate

Model-based screening of compounds for the treatment of Chagas disease, a neglected tropical disease.

Friday 11:35-11:55

D-09

Balancing efficacy and reduction in renal function to optimize initial gentamicin dosing in children with cancer

Friday 11:55-12:15